Intuitive Surgical (NASDAQ:ISRG) Stock Price Up 0.7%

Intuitive Surgical, Inc. (NASDAQ:ISRG) was up 0.7% during mid-day trading on Tuesday . The stock traded as high as $488.48 and last traded at $485.50. Approximately 258,420 shares traded hands during trading, a decline of 83% from the average daily volume of 1,541,943 shares. The stock had previously closed at $482.16.

Wall Street Analyst Weigh In

ISRG has been the subject of several research reports. Citigroup lifted their target price on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research report on Thursday. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and boosted their target price for the company from $380.00 to $510.00 in a research note on Friday, August 2nd. Piper Sandler raised their price target on shares of Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research report on Friday, July 19th. Morgan Stanley increased their price objective on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Finally, Stifel Nicolaus lifted their target price on Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research note on Friday, July 19th. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $444.70.

Intuitive Surgical Price Performance

The firm has a market capitalization of $173.96 billion, a P/E ratio of 88.43, a PEG ratio of 4.97 and a beta of 1.39. The firm’s fifty day moving average price is $446.95 and its 200-day moving average price is $409.81.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same period last year, the firm earned $1.18 EPS. Analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Insider Buying and Selling at Intuitive Surgical

In other news, Director Amal M. Johnson sold 2,943 shares of Intuitive Surgical stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $443.30, for a total value of $1,304,631.90. Following the transaction, the director now owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Robert Desantis sold 584 shares of the stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $404.41, for a total value of $236,175.44. Following the completion of the transaction, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,226,681.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Amal M. Johnson sold 2,943 shares of Intuitive Surgical stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $443.30, for a total value of $1,304,631.90. Following the completion of the transaction, the director now directly owns 12,275 shares in the company, valued at approximately $5,441,507.50. The disclosure for this sale can be found here. In the last three months, insiders sold 15,309 shares of company stock valued at $6,642,470. 0.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. One Wealth Management Investment & Advisory Services LLC increased its stake in shares of Intuitive Surgical by 3.4% in the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock worth $310,000 after purchasing an additional 23 shares during the period. Indiana Trust & Investment Management CO grew its holdings in Intuitive Surgical by 5.3% in the 2nd quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after buying an additional 25 shares during the last quarter. Hoxton Planning & Management LLC grew its holdings in Intuitive Surgical by 4.9% in the 2nd quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock valued at $238,000 after buying an additional 25 shares during the last quarter. First Affirmative Financial Network lifted its holdings in shares of Intuitive Surgical by 2.7% during the second quarter. First Affirmative Financial Network now owns 996 shares of the medical equipment provider’s stock worth $443,000 after buying an additional 26 shares during the last quarter. Finally, Moors & Cabot Inc. lifted its holdings in shares of Intuitive Surgical by 2.3% during the second quarter. Moors & Cabot Inc. now owns 1,159 shares of the medical equipment provider’s stock worth $516,000 after buying an additional 26 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.